What is the price-to-earnings ratio of Novacyt?
The price-earnings ratio of Novacyt is currently 0.01.
Novacyt P/S 2024
Novacyt P/S
0.01
Ticker
ALNOV.PA
ISIN
FR0010397232
WKN
A12CFH
As of Sep 10, 2024, Novacyt's P/S ratio stood at 0.01, a -66.67% change from the 0.03 P/S ratio recorded in the previous year.
The Novacyt P/S history
Novacyt Aktienanalyse
What does Novacyt do?
Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Novacyt's P/S Ratio
Novacyt's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Novacyt's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Novacyt's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Novacyt’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Novacyt stock
How has the price-earnings ratio of Novacyt changed compared to last year?
The price-to-earnings ratio of Novacyt has increased by -66.67% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Novacyt high compared to other companies?
Yes, the price-to-earnings ratio of Novacyt is high compared to other companies.
How does an increase in the price-earnings ratio of Novacyt affect the company?
An increase in the price-earnings ratio of Novacyt would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Novacyt affect the company?
A decrease in the price-earnings ratio of Novacyt would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Novacyt?
Some factors that influence the price-earnings ratio of Novacyt are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Novacyt pay?
Over the past 12 months, Novacyt paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novacyt is expected to pay a dividend of 0 GBP.
What is the dividend yield of Novacyt?
The current dividend yield of Novacyt is .
When does Novacyt pay dividends?
Novacyt pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Novacyt?
Novacyt paid dividends every year for the past 0 years.
What is the dividend of Novacyt?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Novacyt located?
Novacyt is assigned to the 'Health' sector.
Wann musste ich die Aktien von Novacyt kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Novacyt from 9/10/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did Novacyt pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of Novacyt in the year 2023?
In the year 2023, Novacyt distributed 0 GBP as dividends.
In which currency does Novacyt pay out the dividend?
The dividends of Novacyt are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Novacyt
Our stock analysis for Novacyt Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novacyt Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
